Eyelia Eye Drops 0.025% w/v: Contains Brimonidine Tartrate 0.025% w/v.
Eyelia Eye Drops 0.15% w/v: Contains Brimonidine Tartrate 0.15% w/v.
Eyelia Eye Drops 0.2% w/v: Contains Brimonidine Tartrate 0.2% w/v.
Description:
Eyelia ophthalmic solution is an alpha-adrenergic receptor agonist that effectively manages intraocular pressure. The peak ocular hypotensive effect occurs two hours after dosing, and fluorophotometric studies in both animals and humans suggest that Eyelia has a dual mechanism of action. It works by both reducing aqueous humor production and enhancing uveoscleral outflow
Pharmacology:
Brimonidine, the active ingredient in Eyelia, is a highly selective α-2 adrenoreceptor agonist. It reduces intraocular pressure (IOP) in humans when administered topically. Brimonidine Tartrate has minimal effects on cardiovascular parameters when used as directed. The drops have a rapid onset of action, with the peak ocular hypotensive effect occurring two hours after dosing. The effects last for 12 hours or more. Eyelia lowers IOP by reducing aqueous humor production and increasing uveoscleral outflow, providing an effective solution for controlling intraocular pressure.
Eyelia 0.2% ophthalmic solution is used to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Eyelia 0.15% ophthalmic solution is specifically indicated for the control of intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension. Additionally, Eyelia 0.025% ophthalmic solution helps relieve redness in the eye due to minor eye irritations. For optimal use, it is important to follow the guidance of a registered physician.
For Eyelia 0.2% ophthalmic solution, the recommended dosage is one drop in the affected eye(s) three times daily, approximately 8 hours apart. This solution can be used alongside other topical ophthalmic products to lower intraocular pressure, but different products should be administered at least 5 minutes apart. For Eyelia 0.15% ophthalmic solution, the same dosage applies. For Eyelia 0.025% ophthalmic solution, one drop should be instilled into the affected eye(s) every 6 to 8 hours, with a maximum of four applications per day. Again, if multiple topical products are used, they should be applied at least 5 minutes apart.
Although no specific drug interaction studies have been conducted with Eyelia ophthalmic solution, it is important to consider potential interactions with CNS depressants such as alcohol, barbiturates, opiates, sedatives, or anesthetics. As alpha-agonists may reduce pulse and blood pressure, caution is advised when using Eyelia with drugs like beta-blockers (both ophthalmic and systemic), antihypertensives, or cardiac glycosides. Additionally, tricyclic antidepressants may reduce the hypotensive effect of systemic clonidine, and it is not known whether these could interfere with Eyelia's IOP-lowering effects.
Brimonidine Tartrate ophthalmic solution is contraindicated in patients who have a known hypersensitivity to Brimonidine Tartrate. It should also be avoided by patients who are currently receiving monoamine oxidase (MAO) inhibitor therapy, as this could result in adverse effects.
Common side effects of Eyelia include oral dryness, ocular hyperemia, burning and stinging sensations, headaches, blurred vision, foreign body sensation, fatigue, and conjunctival follicles. These adverse events typically occur in 10-30% of patients. Less common side effects reported in 3-9% of patients include corneal staining, photophobia, eyelid erythema, and ocular pain. Rare side effects in less than 3% of patients include lid crusting, conjunctival hemorrhage, abnormal taste, insomnia, depression, and hypertension.
There are no adequate and well-controlled studies regarding the use of Eyelia in pregnant women. In animal studies, Brimonidine crossed the placenta and entered fetal circulation to a limited extent. Therefore, Eyelia should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. It is not known whether Brimonidine is excreted in human milk; however, animal studies suggest it is. A decision should be made whether to discontinue nursing or the drug, considering the importance of the drug to the mother.
Although Eyelia ophthalmic solution has minimal effects on blood pressure, caution should be exercised when treating patients with severe cardiovascular disease. It should also be used cautiously in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans. These patients may need more careful monitoring during treatment with Eyelia.
Eyelia should be stored below 30°C in a cool, dry place, away from light. It is important to keep the bottle out of the reach of children. The dropper tip should not come into contact with any surface to prevent contamination. Do not use the solution after 30 days from the first opening of the bottle.